IN8bio(INAB) - 2023 Q4 - Annual Results

IN8bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights NEW YORK, March 14, 2024 -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today reported financial results and business highlights for the fourth quarter and full-year ended December 31, 2023. "IN8bio entered 2024 with significant momentum behind the company," said William Ho, CEO and co- founder of IN8bio. "Despite the difficult envi ...